Disc Medicine Inc [IRON] stock prices are up 2.61% to $62.63 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IRON shares have gain 3.88% over the last week, with a monthly amount glided 7.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Disc Medicine Inc [NASDAQ: IRON] stock has seen the most recent analyst activity on July 21, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $86. TD Cowen started tracking the stock assigning a Buy rating. Morgan Stanley upgraded its rating to a Overweight but $85 remained the price target by the analyst firm on November 05, 2024. Raymond James upgraded its rating to Strong Buy for this stock on November 04, 2024, and upped its price target to $110. In a note dated October 23, 2024, Jefferies initiated an Buy rating and provided a target price of $89 on this stock.
The stock price of Disc Medicine Inc [IRON] has been fluctuating between $30.82 and $68.73 over the past year. Currently, Wall Street analysts expect the stock to reach $72.5 within the next 12 months. Disc Medicine Inc [NASDAQ: IRON] shares were valued at $62.63 at the most recent close of the market. An investor can expect a potential return of 15.76% based on the average IRON price forecast.
Analyzing the IRON fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.27 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Disc Medicine Inc [NASDAQ:IRON]’s Current Ratio is 32.11. In addition, the Quick Ratio stands at 32.11 and the Cash Ratio stands at 6.18.
Transactions by insiders
Recent insider trading involved Bitterman Kevin, Director, that happened on Aug 22 ’25 when 2287.0 shares were sold. Shareholder, Atlas Venture Opportunity Fund completed a deal on Aug 22 ’25 to buy 2287.0 shares. Meanwhile, Shareholder Atlas Venture Fund X, L.P. bought 4080.0 shares on Aug 22 ’25.
